- Report
- August 2026
- 117 Pages
Global
From €4237EUR$4,750USD£3,634GBP
- Report
- May 2026
- 100 Pages
Global
From €2407EUR$2,699USD£2,065GBP
- Report
- July 2026
- 160 Pages
Global
From €2961EUR$3,320USD£2,540GBP
€3702EUR$4,150USD£3,175GBP
- Report
- June 2025
- 100 Pages
Global
From €4371EUR$4,900USD£3,749GBP
- Report
- August 2022
- 120 Pages
Global
From €4014EUR$4,500USD£3,443GBP
- Report
- June 2025
- 150 Pages
Global
From €2407EUR$2,699USD£2,065GBP
- Report
- June 2025
- 150 Pages
Global
From €2407EUR$2,699USD£2,065GBP
- Drug Pipelines
- June 2025
- 200 Pages
Global
From €2488EUR$2,789USD£2,134GBP
- Report
- May 2024
- 128 Pages
Global
From €2675EUR$2,999USD£2,294GBP
€3567EUR$3,999USD£3,059GBP
- Report
- May 2024
- 130 Pages
Global
From €2675EUR$2,999USD£2,294GBP
€3567EUR$3,999USD£3,059GBP
- Report
- October 2023
- 300 Pages
Global
From €2230EUR$2,500USD£1,913GBP
- Report
- September 2026
- 50 Pages
Global
From €2364EUR$2,650USD£2,027GBP
- Report
- September 2026
- 50 Pages
Global
From €2364EUR$2,650USD£2,027GBP
Metoclopramide is a gastrointestinal drug used to treat symptoms of gastroesophageal reflux disease (GERD), diabetic gastroparesis, and nausea and vomiting. It is a dopamine antagonist that works by blocking the action of dopamine in the brain and gastrointestinal tract. It is available in both oral and injectable forms. Metoclopramide is also used to treat symptoms of Parkinson's disease, such as tremor and stiffness.
Metoclopramide is a widely used drug in the gastrointestinal market. It is used to treat a variety of gastrointestinal conditions, including GERD, gastroparesis, and nausea and vomiting. It is also used to treat symptoms of Parkinson's disease.
The market for metoclopramide is highly competitive, with many companies offering generic and branded versions of the drug. Some of the companies in the market include Pfizer, Novartis, Merck, Sanofi, and Teva Pharmaceuticals. Show Less Read more
